Mirogabalin as a Therapeutic Option for Neuropathic Pain Emerging Postendodontic Treatment: An Observational Study

Area of Science:

• Neurology
• Dentistry
• Pharmacology

Background:

• Post-traumatic trigeminal neuropathic pain (PTTN-occlusal pain) following endodontic treatment presents a clinical challenge.
• Mirogabalin has shown recent clinical efficacy for this specific pain condition.

Purpose of the Study:

• To determine optimal mirogabalin administration duration and dose tapering strategies.
• To establish guidelines for managing PTTN-occlusal pain based on clinical case management.

Main Methods:

• Patients with PTTN-occlusal pain were divided into provisional restoration (n=13) and mirogabalin medication (n=15) groups.
• Mirogabalin (10 mg/day) was administered, with pain intensity monitored using Visual Analog Scale (VAS) diaries.
• Dose reduction and discontinuation protocols were evaluated based on patient adaptation and pain levels.

Main Results:

• The provisional restoration group showed significant VAS score decrease from week 6.
• The mirogabalin group exhibited significant VAS score reduction from week 1.
• Mirogabalin was tapered around week 7 and discontinued by week 11 with no observed pain recurrence.

Conclusions:

• Mirogabalin is an effective treatment for PTTN-occlusal pain.
• A treatment duration of approximately 11 weeks with gradual dose tapering is suggested.
• The study provides a basis for managing PTTN-occlusal pain with mirogabalin.